Kherallah R Yazan, Koneru Srikanth, Krajcer Zvonimir, Preventza Ourania, Dougherty Kathryn G, McCormack Melissa L, Costello Briana T, Coulter Stephanie, Strickman Neil E, Plana Gomez Juan Carlos, Mortazavi Ali, Díez Jose G, Livesay James J, Coselli Joseph S, Silva Guilherme V
Division of Internal Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Department of Cardiology, Texas Heart Institute, Houston, TX, USA.
Ann Cardiothorac Surg. 2021 Sep;10(5):630-640. doi: 10.21037/acs-2021-tviv-131.
Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) has emerged as a safe, effective alternative to redo aortic valve surgery in high-risk patients with degenerated surgical bioprosthetic valves. However, ViV-TAVR has been associated high postprocedural valvular gradients, compared with TAVR for native-valve aortic stenosis.
We performed a retrospective study of all patients who underwent ViV-TAVR for a degenerated aortic valve bioprosthesis between January 1, 2013 and March 31, 2019 at our center. The primary outcome was postprocedural mean aortic valve gradient. Outcomes were compared across surgical valve type (stented versus stentless), surgical valve internal diameter (≤19 versus >19 mm), and transcatheter aortic valve type (self-expanding balloon-expandable).
Overall, 89 patients underwent ViV-TAVR. Mean age was 69.0±12.6 years, 61% were male, and median Society of Thoracic Surgeons Predicted Risk of Mortality score was 5.4 [interquartile range, 3.2-8.5]. Bioprosthesis mode of failure was stenotic (58% of patients), regurgitant (24%), or mixed (18%). The surgical valve was stented in 75% of patients and stentless in 25%. The surgical valve's internal diameter was ≤19 mm in 45% of cases. A balloon-expandable transcatheter valve was used in 53% of procedures. Baseline aortic valve area and mean gradients were 0.87±0.31 cm and 36±18 mmHg, respectively. These improved after ViV-TAVR to 1.38±0.55 cm and 18±11 mmHg at a median outpatient follow-up of 331 [67-394] days. Higher postprocedural mean gradients were associated with surgical valves having an internal diameter ≤19 mm (24±13 versus 16±8, P=0.002) and with stented surgical valves (22±11 versus 12±6, P<0.001).
ViV-TAVR is an effective option for treating degenerated surgical aortic bioprostheses, with acceptable hemodynamic outcomes. Small surgical valves and stented surgical valves are associated with higher postprocedural gradients.
对于外科生物人工心脏瓣膜退化的高危患者,经导管主动脉瓣置换术(ViV-TAVR)已成为再次主动脉瓣手术的一种安全、有效的替代方案。然而,与用于治疗原发性主动脉瓣狭窄的经导管主动脉瓣置换术(TAVR)相比,ViV-TAVR术后瓣膜梯度较高。
我们对2013年1月1日至2019年3月31日在本中心接受ViV-TAVR治疗退化性主动脉瓣生物人工心脏瓣膜的所有患者进行了一项回顾性研究。主要结局是术后平均主动脉瓣梯度。根据手术瓣膜类型(带支架与无支架)、手术瓣膜内径(≤19 mm与>19 mm)和经导管主动脉瓣类型(自膨胀与球囊扩张)比较结局。
总体而言,89例患者接受了ViV-TAVR。平均年龄为69.0±12.6岁,61%为男性,胸外科医师协会预测死亡率评分中位数为5.4[四分位间距,3.2-8.5]。生物人工心脏瓣膜的失效模式为狭窄(58%的患者)、反流(24%)或混合(18%)。75%的患者手术瓣膜为带支架的,25%为无支架的。45%的病例中手术瓣膜内径≤19 mm。53%的手术使用了球囊扩张型经导管瓣膜。基线主动脉瓣面积和平均梯度分别为0.87±0.31 cm和36±18 mmHg。在门诊中位随访331[67-394]天时,ViV-TAVR术后这些指标改善为1.38±0.55 cm和18±11 mmHg。术后平均梯度较高与内径≤19 mm的手术瓣膜(24±13与16±8,P=0.002)以及带支架的手术瓣膜(22±11与12±6,P<0.001)相关。
ViV-TAVR是治疗退化性外科主动脉生物人工心脏瓣膜的有效选择,血流动力学结局可接受。小型手术瓣膜和带支架的手术瓣膜与术后较高的梯度相关。